NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement

NovoCure Ltd

CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.
Company estimates approximately $13 million per month in lost revenue from CMS payors until privileges are reinstated.
NovoCure has filed a Corrective Action Plan and expects reinstatement, but cannot predict timing with certainty.
Company continues to provide services to existing and new patients; will attempt to bill for services during reinstatement.
Financial impact and ultimate outcome cannot be determined at this time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.